RLN2 and hydrops fetalis: Consequently, it is predicted that relaxin-2 could be a valuable biomarker for the identification of high-risk patients and direct clinical treatment, as well as for the evaluation of HF prognosis, representing a promising target for future therapeutic strategies [70,98].